Francesca Palombi

Rome, Italy

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 29 publications

TALOs, Fill the Gap: Tafasitamab and Lenalidomide in Diffuse Large B-Cell Lymphoma in the Real-Life Patient Journey.

TALOs, Fill the Gap: Tafasitamab and Lenalidomide in Diffuse Large B-Cell Lymphoma in the Real-Life Patient Journey.

Journal: Hematological oncology

Published: September 02, 2025

Erratum to: Bendamustine and rituximab as first-line treatment for symptomatic splenic marginal zone lymphoma: long-term outcome and impact of early unmeasurable minimal residual disease attainment from the BRISMA/IELSG36 phase II study.

Erratum to: Bendamustine and rituximab as first-line treatment for symptomatic splenic marginal zone lymphoma: long-term outcome and impact of early unmeasurable minimal residual disease attainment from the BRISMA/IELSG36 phase II study.

Journal: Haematologica

Published: April 01, 2025

A predictive serum miRNA signature impacts diffuse large B-cell lymphoma cell viability via inhibition of EGLN1 and TXNRD1 regulators of ferroptosis.

A predictive serum miRNA signature impacts diffuse large B-cell lymphoma cell viability via inhibition of EGLN1 and TXNRD1 regulators of ferroptosis.

Journal: British journal of haematology

Published: February 14, 2025

Bendamustine and rituximab as first-line treatment for symptomatic splenic marginal zone lymphoma: long-term outcome and impact of early unmeasurable minimal residual disease attainment from the BRISMA/IELSG36 phase II study.

Bendamustine and rituximab as first-line treatment for symptomatic splenic marginal zone lymphoma: long-term outcome and impact of early unmeasurable minimal residual disease attainment from the BRISMA/IELSG36 phase II study.

Journal: Haematologica

Published: March 07, 2024

Efficacy and safety of biosimilar Peg-filgrastim after autologous stem cell transplant in myeloma and lymphoma patients: a comparative study with biosimilar Filgrastim, Lenograstim, and originator Peg-filgrastim.

Efficacy and safety of biosimilar Peg-filgrastim after autologous stem cell transplant in myeloma and lymphoma patients: a comparative study with biosimilar Filgrastim, Lenograstim, and originator Peg-filgrastim.

Journal: Annals of hematology

Published: November 17, 2023

IELSG38: phase II trial of front-line chlorambucil plus subcutaneous rituximab induction and maintenance in mucosa-associated lymphoid tissue lymphoma.

IELSG38: phase II trial of front-line chlorambucil plus subcutaneous rituximab induction and maintenance in mucosa-associated lymphoid tissue lymphoma.

Journal: Haematologica

Published: August 14, 2023

Reverse strategy to locally advanced breast implant-associated anaplastic large cell lymphoma: A case report.

Reverse strategy to locally advanced breast implant-associated anaplastic large cell lymphoma: A case report.

Journal: Frontiers in oncology

Published: October 05, 2022

Obinutuzumab does not improve complete methabolic response but does not compromise mobilization or engraftment of autologous peripheral blood stem cells in diffuse large B cell lymphoma: Results from a fondazione italiana linfomi prospective phase II study (the GIOTTO study).

Obinutuzumab does not improve complete methabolic response but does not compromise mobilization or engraftment of autologous peripheral blood stem cells in diffuse large B cell lymphoma: Results from a fondazione italiana linfomi prospective phase II study (the GIOTTO study).

Journal: Hematological oncology

Published: March 13, 2022

Impact of anti-CD20 monoclonal antibodies on serologic response to BNT162b2 vaccine in B-cell Non-Hodgkin's lymphomas.

Impact of anti-CD20 monoclonal antibodies on serologic response to BNT162b2 vaccine in B-cell Non-Hodgkin's lymphomas.

Journal: Leukemia

Published: June 15, 2021

MiR-22, a serum predictor of poor outcome and therapy response in diffuse large B-cell lymphoma patients.

MiR-22, a serum predictor of poor outcome and therapy response in diffuse large B-cell lymphoma patients.

Journal: British journal of haematology

Published: May 19, 2021

Dose-dense ABVD as first-line therapy in early-stage unfavorable Hodgkin lymphoma: results of a prospective, multicenter double-step phase II study by Fondazione Italiana Linfomi.

Dose-dense ABVD as first-line therapy in early-stage unfavorable Hodgkin lymphoma: results of a prospective, multicenter double-step phase II study by Fondazione Italiana Linfomi.

Journal: Annals of hematology

Published: February 04, 2021

Role of Pregabalin in Treatment of Polyneuropathy in Multiple Myeloma Patients: A Retrospective Study.

Role of Pregabalin in Treatment of Polyneuropathy in Multiple Myeloma Patients: A Retrospective Study.

Journal: Clinical neuropharmacology

Published: July 31, 2019

Showing 1-12 of 29

Last Updated: 09/26/2026